Pharmaceutical composition containing m-diamide compound and application thereof
阅读说明：本技术 一种含有间二酰胺类化合物的药物组合物及其应用 (Pharmaceutical composition containing m-diamide compound and application thereof ) 是由 倪珏萍 相君成 吕亮 洪湖 刘吉永 邵佳礼 周丽琪 刘叙杆 于 2019-07-31 设计创作，主要内容包括：本发明提供一种含有间二酰胺类化合物的药物组合物及其应用,所述药物组合物包括有效成分A和有效成分B,所述有效成分A为具有式I所示结构的间二酰胺类化合物,所述有效成分B包括其他杀虫剂中任意一种或两种的组合。本发明中含有效成分A和有效成分B的组合物,具有协同增效、治理抗性害虫,扩大活性谱、控制传毒昆虫等独特作用,可有效防治水稻、玉米、小麦、蔬菜、果树、花卉、油料、糖料等作物及园艺、林业上的多种病虫害。(The invention provides a pharmaceutical composition containing a m-diamide compound and application thereof, wherein the pharmaceutical composition comprises an active ingredient A and an active ingredient B, the active ingredient A is the m-diamide compound with a structure shown in a formula I, and the active ingredient B comprises any one or a combination of two of other insecticides. The composition containing the effective component A and the effective component B has the unique effects of synergy, controlling resistant pests, expanding an activity spectrum, controlling toxic insects and the like, and can effectively prevent and control various plant diseases and insect pests in crops such as rice, corn, wheat, vegetables, fruit trees, flowers, oil plants, sugar and the like, and in gardening and forestry.)
1. A pharmaceutical composition containing a m-diamide compound is characterized by comprising an active ingredient A and an active ingredient B, wherein the active ingredient A is an amide compound with a structure shown in a formula II,
the effective component B comprises isoprocarb, diflubenzuron, pirimicarb, fenitrothion, profenofos, hexaflumuron, methomyl, monosultap, dimehypo, phoxim, dichlorvos, tebufenozide, deltamethrin, cypermethrin, cyromazine, lambda-cyhalothrin, chlorpyrifos, acephate, bifenthrin, carbosulfan, thiocyclam, cartap, triazophos, fenpropathrin, ethofenprox and pyriproxyfen;
in the formula II, the reaction mixture is shown in the specification,
z is selected from hydrogen, fluorine, chlorine, bromine, iodine, cyano, C1-C3Haloalkyl, C1-C3Haloalkoxy or C1-C3An alkylsulfonyl group;
y is selected from trifluoromethyl or trifluoromethoxy;
r is selected from hydrogen or methyl.
2. The pharmaceutical composition containing the m-diamide compound according to claim 1, wherein in formula II,
z is selected from hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethoxy, trifluoromethyl, methylsulfonyl or trifluoromethylsulfonyl;
y is selected from trifluoromethyl or trifluoromethoxy;
r is selected from hydrogen or methyl.
3. The pharmaceutical composition containing the m-diamide compound according to claim 1 or 2, wherein the m-diamide compound is any one selected from the following compounds 1 to 14:
4. the pharmaceutical composition containing the m-diamide compound as claimed in any one of claims 1 to 3, wherein the weight ratio of the active ingredient A to the active ingredient B is 200:1-1: 200;
preferably, when the active ingredient B in the pharmaceutical composition containing the m-diamide compound is chlorpyrifos, acephate, phoxim, dichlorvos, fenitrothion, profenofos or triazophos, the weight ratio of the active ingredient A to the active ingredient B is 100:1-1: 100;
preferably, when the active ingredient B in the pharmaceutical composition containing the m-diamide compound is lambda-cyhalothrin, deltamethrin, cypermethrin, bifenthrin, ethofenprox or fenpropathrin, the weight ratio of the active ingredient A to the active ingredient B is 60: 1-1: 60;
preferably, when the active ingredient B in the pharmaceutical composition containing the m-diamide compound is isoprocarb, methomyl, carbosulfan or pirimicarb, the weight ratio of the active ingredient A to the active ingredient B is 80:1-1: 80;
preferably, when the active ingredient B in the pharmaceutical composition containing the m-diamide compound is monosultap, dimehypo, thiocyclam or cartap, the weight ratio of the active ingredient A to the active ingredient B is 100:1-1: 100;
preferably, when the active ingredient B in the pharmaceutical composition containing the m-diamide compound is diflubenzuron, hexaflumuron, cyromazine, pyriproxyfen or tebufenozide, the weight ratio of the active ingredient A to the active ingredient B is 80:1-1: 80.
5. The pharmaceutical composition containing the m-diamide compound as claimed in any one of claims 1 to 4, wherein the pharmaceutical composition comprises a combination of compound 1 and isoprocarb in a weight ratio of 1:4, a combination of compound 1 and diflubenzuron in a weight ratio of 80:1 to 1: 80;
preferably, the pharmaceutical composition comprises compound 2 in combination with pirimicarb in a weight ratio of 1: 2;
preferably, the pharmaceutical composition comprises the combination of the compound 3 and fenitrothion in a weight ratio of 1:62.5, the combination of the compound 3 and profenofos in a weight ratio of 1:20, the combination of the compound 3 and diflubenzuron in a weight ratio of 1:50, and the combination of the compound 3 and hexaflumuron in a weight ratio of 1: 20;
preferably, the pharmaceutical composition comprises a combination of the compound 4 and the methomyl in a weight ratio of 3:5, a combination of the compound 4 and the monosultap in a weight ratio of 1:200, a combination of the compound 4 and the monosultap in a weight ratio of 100:1-1:100, and a combination of the compound 4 and the dimehypo in a weight ratio of 1: 200.
6. The pharmaceutical composition containing the m-diamide compound as claimed in any one of claims 1 to 5, which comprises a combination of compound 5 and phoxim in a weight ratio of 1:37.5, a combination of compound 5 and dichlorvos in a weight ratio of 1:37.5, a combination of compound 5 and monosultap in a weight ratio of 1:80, a combination of compound 5 and tebufenozide in a weight ratio of 1: 25;
preferably, the pharmaceutical composition comprises a combination of the compound 6 and deltamethrin in a weight ratio of 100:1, a combination of the compound 6 and cypermethrin in a weight ratio of 5:1, a combination of the compound 6 and monosultap in a weight ratio of 1:80, and a combination of the compound 6 and cyromazine in a weight ratio of 80:1-1: 80;
preferably, the pharmaceutical composition comprises the combination of the compound 7 and monosultap in a weight ratio of 1:160, the combination of the compound 7 and isoprocarb in a weight ratio of 80:1-1:80, and the combination of the compound 7 and lambda-cyhalothrin in a weight ratio of 60: 1-1: 60;
preferably, the pharmaceutical composition comprises a combination of a compound 8 and chlorpyrifos in a weight ratio of 100:1-1:100, a combination of the compound 8 and acephate in a weight ratio of 1:25, a combination of the compound 8 and lambda-cyhalothrin in a weight ratio of 25:1, a combination of the compound 8 and bifenthrin in a weight ratio of 5:1, a combination of the compound 8 and carbosulfan in a weight ratio of 2:1, a combination of the compound 8 and thiocyclam in a weight ratio of 1:160, and a combination of the compound 8 and cartap in a weight ratio of 1: 200;
preferably, the pharmaceutical composition comprises compound 9 in combination with monosultap in a weight ratio of 1: 80;
preferably, the pharmaceutical composition comprises the combination of the compound 10 and the chlorpyrifos in a weight ratio of 1:20, the combination of the compound 10 and the triazophos in a weight ratio of 1:20, and the combination of the compound 10 and the monosultap in a weight ratio of 1: 160;
preferably, the pharmaceutical composition comprises a combination of compound 11 and fenpropathrin in a weight ratio of 2.5:1, a combination of compound 11 and ethofenprox in a weight ratio of 2:1, a combination of compound 11 and monosultap in a weight ratio of 1: 64;
preferably, the pharmaceutical composition comprises compound 12 in combination with monosultap in a weight ratio of 1: 80;
preferably, the pharmaceutical composition comprises compound 13 in combination with monosultap in a weight ratio of 1: 160;
preferably, the pharmaceutical composition comprises the compound 14 and pyriproxyfen in a weight ratio of 80:1-1: 80.
7. A pharmaceutical preparation, which comprises the pharmaceutical composition containing the m-diamide compound of any one of claims 1-6 and an agriculturally pharmaceutically acceptable adjuvant and/or carrier;
preferably, the agriculturally and pharmaceutically acceptable auxiliary agent comprises any one or a combination of at least two of a dispersing agent, a wetting agent, an emulsifying agent, an antifreezing agent, a thickening agent, an antifoaming agent, a preservative, a stabilizing agent or a coloring agent;
preferably, the carrier comprises a filler and/or a solvent;
preferably, the dosage form of the pharmaceutical preparation is soluble solution, soluble powder, soluble granule, missible oil, wettable powder, aqueous emulsion, suspending agent, dispersible oil suspending agent, water dispersible granule, microcapsule suspending agent, granule, microemulsion, suspoemulsion, microcapsule suspension-suspending agent, ultra-low volume liquid, hot fogging concentrate, film-spreading oil agent, suspended seed coating agent, seed treatment dry powder, seed treatment suspending agent, seed treatment soluble powder, seed treatment dispersible powder, seed treatment emulsion or seed treatment liquid;
preferably, the dosage form of the pharmaceutical preparation is soluble agent, soluble granule, suspending agent, missible oil, wettable powder, aqueous emulsion, water dispersible granule, dispersible oil suspending agent, microcapsule suspending agent, ultra-low volume liquid, hot fogging concentrate, suspended seed coating agent or seed treatment dispersible powder.
8. The pharmaceutical preparation according to claim 7, wherein the content of the pharmaceutical composition containing the m-diamide compound in the pharmaceutical preparation is 0.01-99% by weight, preferably 0.5-95% by weight.
9. Use of the pharmaceutical composition according to any one of claims 1 to 6 or the pharmaceutical formulation according to claim 7 or 8 for controlling plant diseases or insect pests in agriculture, forestry, horticulture;
preferably, application is by spraying, pouring or seed treatment.
10. A method for controlling plant diseases and insect pests, which is characterized by comprising the following steps: applying an effective dose of a pharmaceutical composition containing a m-diamide compound as claimed in any one of claims 1-6 or a pharmaceutical formulation as claimed in claim 7 or 8 to a medium in which a plant pest or growth thereof is to be controlled;
preferably, the effective dose is from 10 to 1000g per hectare, preferably from 15 to 900g per hectare.
Technical Field
The invention belongs to the technical field of pest control by using a pharmaceutical composition, and relates to a pharmaceutical composition containing a m-diamide compound and application thereof.
Background
In the production of crops such as agriculture and horticulture, the damage caused by plant diseases and insect pests is still very obvious, and the development of new pesticides or pesticide compositions with better activity, lower dosage and more environment-friendly property is always needed for the reasons that pests have resistance to the existing pesticides and the existing pesticides are not environment-friendly.
For example, CN101208009A discloses that compositions containing m-diamide compounds have insecticidal effects, and insecticides and fungicides of various structural types in the prior art are widely used for various crops. With the continuous use of pesticides, pests and diseases can generate resistance to some existing pesticide products, and the insecticidal activity of the existing pesticide varieties can not always meet the needs of many agricultural practices.
The pesticide composition has important functions of improving the control effect of the pesticide, expanding the control spectrum and delaying the generation of resistance. Therefore, in the art, it is still desired to develop more efficient pesticide compositions or pesticidal and bactericidal compositions to meet the needs of agriculture as well as forestry.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to provide a pharmaceutical composition containing a m-diamide compound and application thereof, wherein the pharmaceutical composition has a synergistic effect and can be used for preventing and treating various agricultural and forestry insect pests and diseases caused by insects, diseases and the like.
In order to achieve the purpose, the invention adopts the following technical scheme:
in one aspect, the invention provides a pharmaceutical composition containing a m-diamide compound, which comprises an active ingredient A and an active ingredient B, wherein the active ingredient A is an amide compound with a structure shown in formula I, and the active ingredient B comprises any one or a combination of two of other insecticides or bactericides;
wherein Z is selected from hydrogen, fluorine, chlorine, bromine, iodine, cyano, nitro, substituted or unsubstituted 3-to 10-membered heterocyclic group, C1-C6Alkyl radical, C1-C6Haloalkyl, C1-C6Alkoxy radical, C1-C6Haloalkoxy, C1-C6Alkylsulfinyl radical, C1-C6Haloalkylsulfinyl radical, C1-C6Alkylsulfonyl or C1-C6A haloalkylsulfonyl group; q is selected from C3-C8Cycloalkyl or C3-C8A halocycloalkyl group;
x is selected from hydrogen, fluorine or trifluoromethyl;
Y1selected from fluorine, chlorine, bromine, iodine, cyano, nitro, C1-C6Alkyl radical, C1-C6Haloalkyl, C1-C6Haloalkoxy, C2-C4Alkenyl radical, C2-C4Haloalkenyl, C2-C4Alkynyl, C2-C4Halogenated alkynyl, C3-C8Cycloalkyl radical, C3-C8Halogenocycloalkyl, C1-C6Alkylcarbonyl group, C1-C6Alkylsulfinyl radical, C1-C6Haloalkylsulfinyl radical, C1-C6Alkylsulfonyl or C1-C6A haloalkylsulfonyl group;
Y2selected from bromine, iodine, cyano, nitro, C1-C6Haloalkyl, C1-C6Haloalkoxy, C2-C4Alkenyl radical, C2-C4Haloalkenyl, C2-C4Alkynyl, C2-C4Halogenated alkynyl, C3-C8Cycloalkyl radical, C3-C8Halogenocycloalkyl, C1-C6Alkylcarbonyl group, C1-C6Alkylsulfinyl radical, C1-C6Haloalkylsulfinyl radical, C1-C6Alkylsulfonyl or C1-C6A haloalkylsulfonyl group;
R1selected from hydrogen, fluoro or methoxy; r2Selected from fluoro or trifluoromethyl; r3And R4Each independently selected from hydrogen, halogen, cyano, nitro, C1-C6Alkyl radical, C1-C6Haloalkyl, C3-C8Cycloalkyl or C3-C8A halocycloalkyl group;
m represents an integer of 0 to 5 (e.g., 0, 1,2,3, 4, or 5); n represents an integer of 0 to 3 (for example, 0, 1,2 or 3); w1And W2Independently an oxygen atom or a sulfur atom.
The m-diamide compound with the structure shown in the formula I is used as an effective component A and is matched with a medicinal composition of an effective component B, due to the synergistic interaction between the effective component A and the effective component B, on one hand, the use amount of a single active component can be reduced, on the other hand, the prevention and treatment effect is remarkably improved, and due to the fact that the effective component A can achieve better insecticidal activity at low dose, the effect is fast to take effect and good quick-acting performance is achieved, the medicinal composition containing the m-diamide compound also has good quick-acting performance, and due to the fact that the effect is good at low dose, damage to plants and human beings caused by overlarge medicament concentration is reduced, and the m-diamide compound generates less medicament residue during application and is more beneficial to environmental protection.
Preferably, the invention provides a pesticide composition containing a compound with m-diamide 3 position substituted by N-cyclopropylmethyl derivative, which comprises an effective component A and an effective component B, wherein the effective component A is a m-diamide compound with a structure shown in formula II, and the effective component B comprises any one or a combination of two of other bactericides, insecticides or acaricides;
in the formula II, the reaction mixture is shown in the specification,
z is selected from hydrogen, fluorine, chlorine, bromine, iodine, cyano, C1-C6Haloalkyl, C1-C6Haloalkoxy, C1-C6Alkylsulfonyl or C1-C6A haloalkylsulfonyl group;
y is selected from C1-C6Haloalkyl or C1-C6A haloalkoxy group;
r is selected from hydrogen or methyl.
In the invention, the m-diamide compound with the structure shown in the formula II is further preferably selected to be matched with the effective component B as the effective component of the pharmaceutical composition, the m-diamide compound and the effective component B have synergistic interaction, the onset of action is fast, the quick-acting property is good, the good effect can be achieved under the condition of low dosage, the drug residue is less, and the environmental protection is facilitated.
In the present invention, as a preferred embodiment, in formula I, Z is selected from hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethoxy, trifluoromethyl, methylsulfonyl or trifluoromethylsulfonyl; y is selected from trifluoromethyl or trifluoromethoxy; r is selected from hydrogen or methyl.
In a further preferred embodiment of the present invention, the m-diamide compound is any one of compounds represented by the following table 1 having the general formula II.
TABLE 1 active ingredient A
In Table 1, H is a hydrogen atom, F is a fluorine atom, Cl is a chlorine atom, Br is a bromine atom, I is an iodine atom, CN is a cyano group, CF3Is trifluoromethyl, OCF3Is trifluoromethoxy, MeS (O)2Represents methylsulfonyl, CF3S(O)2Represents trifluoromethanesulfonyl.
In the present invention, as a particularly preferred embodiment, the m-diamide compound is any one or a combination of at least two selected from the following compounds 1 to 14:
the term "C" as used in the present invention1-C6Alkyl "refers to a straight or branched chain alkyl group having 1 to 6 carbon atoms, including, without limitation, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, and the like. The term "C1-C6Alkoxy "refers to a straight or branched chain alkoxy group having 1 to 6 carbon atoms, including without limitation methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, and the like. The term "C1-C6Haloalkyl "refers to an alkyl group of 1 to 6 carbon atoms having halogen substitution, including without limitation chloromethyl, 1-chloroethyl, 2-bromo-n-propyl, and the like. The term "C1-C6Haloalkoxy "refers to alkoxy groups of 1 to 6 carbon atoms having halogen substitution; all in oneThe term "C3-C8Cycloalkyl "refers to a cyclic alkyl group having 3 to 8 carbon atoms in the ring, including without limitation cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and the like; as used herein, the term "C3-C8 halocycloalkyl" refers to a cyclic alkyl group of 3 to 8 carbon atoms having halogen substitution in the ring, including, without limitation, 1-chlorocyclopropyl, 1-fluorocyclopropyl, perfluorocyclopropyl, 1-chlorocyclobutyl, 1-chlorocyclopentyl, and the like.
In the present invention, C before the specific group1-C6、C3-C8Etc. represent the number of carbon atoms contained in the radical, e.g. C1-C6Represents a group having 1,2,3, 4, 5 or 6 carbon atoms, C3-C8Represents a group in which the number of carbon atoms may be 3, 4, 5, 6, 7 or 8, and so on.
The effective component B is selected from organophosphorus, pyrethroid, carbamate, nereistoxin or insect growth regulator.
Preferably, the organophosphorus insecticide is selected from chlorpyrifos, acephate, phoxim, dichlorvos, triazophos, profenofos, fosthiazate, malathion, fenitrothion, dimethoate, omethoate, diazinon, isocarbophos or a combination of at least two of the foregoing;
preferably, the synthetic pyrethroid insecticide is selected from the group consisting of lambda-cyhalothrin, deltamethrin, bifenthrin, cypermethrin, ethofenprox, fenpropathrin, fenvalerate, cycloprothrin, cyfluthrin, tefluthrin, tralomethrin, proffluthrin, permethrin, silafluofen, phenothrin, flucythrinate and their various isomers or a combination of at least two of the pyrethroid insecticides.
Preferably, the carbamate pesticide is selected from methomyl, isoprocarb, fenobucarb, carbosulfan, pirimicarb, fenoxycarb or a combination of at least two of the foregoing;
preferably, the nereistoxin insecticide is selected from monosultap, dimehypo, thiocyclam, cartap or a combination of at least two of the two;
preferably, the insect growth regulator is selected from chlorfluazuron, diflubenzuron, hexaflumuron, flufenoxuron, chlorbenzuron, cyromazine, pyriproxyfen, fenoxycarb, tebufenozide, methazine, or a combination of at least two thereof.
In actual production, the traditional organophosphorus, pyrethroid, carbamate and nereistoxin insecticides have no good effect for long-term use or unreasonable use, and the dosage has to be increased when in use.
The insect growth regulator can control pests by preventing the special development processes of molting, metamorphosis and the like of insects, is safe to human and livestock, and is greatly researched and applied; but the problem of poor quick action needs to be compensated by compounding with other medicaments.
As a further preferred embodiment of the present invention, the pharmaceutical composition containing the m-diamide compound is a pharmaceutical composition containing the m-diamide compound (active ingredient a) and the active ingredient B shown in table 2 below, but not limited to the combinations listed in the table.
TABLE 2
The pests such as chilo suppressalis, plutella xylostella, armyworm, alfalfa aphid, brown planthopper, leaf miner, bemisia tabaci and the like are adopted to test the combined action of the pharmaceutical composition, and the composition with the synergistic action is found.
The weight ratio of the active ingredient A to the active ingredient B is 200:1-1:200, such as 200:1, 180:1, 150:1, 130:1, 100:1, 80:1, 60:1, 40:1, 20:1, 10:1, 1:10, 1:30, 1:50, 1:80, 1:100, 1:120, 1:140, 1:160, 1:180 or 1: 200.
In the present invention, the preferable weight ratio of the pharmaceutical composition containing the m-diamide compound is different according to the effective component a and the effective component B contained therein, and as a preferable embodiment of the present invention, when the effective component a and the effective component B are selected from the components shown in table 3, the preferable weight ratio and the particularly preferable weight ratio are shown in table 3.
TABLE 3
In the present invention, the m-diamide compounds may also be replaced with tautomers, enantiomers, diastereomers, or salts thereof.
In the invention, the pharmaceutical composition containing the tautomer, enantiomer, diastereomer or salt of the m-diamide compound can also exert the same action and effect as the pharmaceutical composition containing the m-diamide compound, and has good insecticidal effect and quick action at low dosage.
In another aspect, the present invention provides a pharmaceutical preparation, which comprises the pharmaceutical composition containing the m-diamide compound as described above, and an agriculturally and pharmaceutically acceptable adjuvant and/or carrier.
Preferably, the pharmaceutical composition containing the m-diamide compound is contained in the pharmaceutical preparation in an amount of 0.01 to 99% by weight, for example, 0.01%, 0.1%, 1%, 3%, 5%, 8%, 10%, 15%, 18%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99%.
Preferably, the agriculturally pharmaceutically acceptable auxiliary agent includes any one of a dispersant, a wetting agent, an emulsifier, an antifreeze agent, a thickener, an antifoaming agent, a preservative, a stabilizer or a coloring agent or a combination of at least two thereof.
Preferably, the dispersant comprises lignosulfonate, alkylphenol polyoxyethylene ether, sodium salt of naphthalene sulfonic acid formaldehyde condensate, fatty amine polyoxyethylene ether, fatty acid polyoxyethylene ester, glycerol fatty acid ester polyoxyethylene ether, polycarboxylate, formaldehyde condensate, calcium salt of alkylbenzene sulfonic acid, and alkylphenol polyoxyethylene ether. The wetting agent is selected from sodium dodecyl sulfate, alkyl naphthalene sulfonate, nekal BX, polyoxyethylene ether, EO/PO block polyether, fatty alcohol-polyoxyethylene ether sulfate, sodium alkyl phosphate, alkyl naphthalene sulfonate and alkylphenol polyoxyethylene sodium sulfate. The emulsifier is selected from dodecyl benzene sulfonate, alkyl naphthalene sulfonate, alkyl sulfonate, alkylphenol polyoxyethylene, benzyl phenol polyoxyethylene, phenethyl phenol polyoxyethylene and fatty amine polyoxyethylene. The antifreeze is selected from ethylene glycol, propylene glycol and glycerol. The thickener is selected from xanthan gum, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl starch, methyl cellulose, sodium starch phosphate, magnesium aluminum silicate and polyvinyl alcohol. The defoaming agent is selected from silicone oil, silicone compounds, tributyl phosphate, C10-C20 saturated fatty acid compounds and polyether defoaming agents. The preservative is selected from formaldehyde, phenyl salicylate, butyl p-hydroxybenzoate and potassium sorbate, the stabilizer is selected from triphenyl phosphite, epoxy chloroalkane, epoxy soybean oil and magnesium aluminum silicate, and the coloring agent is selected from azo pigment, titanium oxide and iron oxide.
Preferably, the carrier comprises a filler and/or a solvent;
preferably, the agriculturally pharmaceutically acceptable carrier includes a solid carrier and/or a liquid carrier.
Preferably, the solid support comprises natural or synthetic clays and silicates, such as natural silica and diatomaceous earth; magnesium silicates such as talc; magnesium aluminum silicates such as kaolinite, montmorillonite and mica; white carbon black, calcium carbonate, light calcium carbonate; calcium sulfate; limestone; sodium sulfate; amine salts such as ammonium sulfate, hexamethylene diamine. Liquid carriers include water and organic solvents including aromatic hydrocarbons such as trimethylbenzene, benzene, xylene, toluene, and the like; chlorinated hydrocarbons such as chlorobenzene, vinyl chloride, chloroform, dichloromethane, etc.; aliphatic hydrocarbons such as petroleum fractions, cyclohexane, light mineral oil; alcohols such as isopropanol, butanol, ethylene glycol, propylene glycol, glycerol and cyclohexanol and ethers and esters thereof; ketones such as acetone, cyclohexanone, and dimethylformamide and N-methyl-pyrrolidone.
The active ingredient may be mixed with a liquid carrier and/or a solid carrier during the formulation of the pesticidal composition (i.e., the pharmaceutical preparation), while adding adjuvants such as emulsifiers, dispersants, stabilizers, wetting agents, binders, antifoaming agents, antioxidants, and the like.
Preferably, the dosage form of the pharmaceutical preparation is soluble solution, soluble powder, soluble granule, missible oil, wettable powder, aqueous emulsion, suspending agent, dispersible oil suspending agent, water dispersible granule, microcapsule suspending agent, granule, microemulsion, suspoemulsion, microcapsule suspension-suspending agent, ultra-low volume liquid, hot fogging concentrate, film-spreading oil agent, suspended seed coating agent, seed treatment dry powder, seed treatment suspending agent, seed treatment soluble powder, seed treatment dispersible powder, seed treatment emulsion or seed treatment liquid.
Preferably, the dosage form of the pharmaceutical preparation is soluble agent, soluble granule, suspending agent, missible oil, wettable powder, aqueous emulsion, water dispersible granule, dispersible oil suspending agent, microcapsule suspending agent, ultra-low volume liquid, hot fogging concentrate, suspended seed coating agent or seed treatment dispersible powder.
In another aspect, the invention provides the application of the pharmaceutical composition or the pharmaceutical preparation containing the m-diamide compound in the prevention and treatment of plant diseases or insect pests in agriculture, forestry and horticulture.
The pharmaceutical composition or pharmaceutical preparation containing the m-diamide compound is suitable for preventing and treating various agricultural and forestry and horticultural insect pests and sanitary pests and diseases harmful to rice, corn, wheat, potatoes, fruit trees, vegetables, other crops, flowers and the like.
The composition has wide application range, and the applied plants or crops mainly comprise the following types: vegetables, cucumber, luffa, watermelon, melon, pumpkin, snake gourd, spinach, celery, cabbage, gourd, pepper, eggplant, tomato, shallot, ginger, garlic, leek, strawberry, asparagus lettuce, kidney bean, cowpea, broad bean, radish, carrot, potato, yam; cereals, wheat, barley, corn, rice, sorghum; fruit trees, apples, pears, bananas, oranges, grapes, litchis and mangoes; flowers, peony, rose, and crane; oil crops, peanuts, soybeans, rape, sunflowers, sesame; sugar crops, sugar beets, sugar cane; other crops, such as potato, sweet potato, tobacco and tea; horticulture, forestry, home health, public health areas, and the like; the above list of plant or crop ranges has no limiting effect on the range of use of the pharmaceutical composition.
In the present invention, the pests include lepidoptera, coleoptera, hemiptera, thysanoptera, diptera, orthoptera, homoptera, isoptera, hymenoptera, spider mite pests, and the diseases include diseases caused by deuteromycetes, ascomycetes, basidiomycetes, and the like.
Preferably, the pests include, but are not limited to: cotton bollworm, plutella xylostella, asparagus caterpillar, prodenia litura, cabbage caterpillar, chilo suppressalis, tryporyza incertulas, sesamia inferens, fall armyworm, rice leaf roller, rice thrips, western flower thrips, melon thrips, spring onion thrips, ginger thrips, mango thrips, peach aphid, cotton aphid, alfalfa aphid, apple yellow aphid, wheat aphid, flea beetle, stinkbug, gray planthopper, brown planthopper, white back planthopper, termite, mosquito fly, carmine spider mite and citrus red spider. The diseases include but are not limited to wheat scab, rice sheath blight, rice blast and the like.
In the present invention, the pharmaceutical composition or pharmaceutical preparation is used in the form of spray, soil treatment, seed treatment, flying prevention, and the like.
In another aspect, the invention provides the use of a pharmaceutical composition comprising a isophthalamide compound, as described above, in the seed treatment of plants, crops or flowers.
In another aspect, the present invention provides a method for controlling plant diseases and insect pests, the method comprising: applying an effective dose of the pharmaceutical composition or the pharmaceutical preparation containing the m-diamide compound to a medium needing to control plant diseases or the growth of the plant diseases.
Preferably, the effective dose is from 10 to 1000g per hectare, for example 10g, 20g, 50g, 80g, 100g, 120g, 150g, 180g, 200g, 250g, 300g, 350g, 400g, 450g, 500g, 600g, 700g, 800g, 900g or 1000g, preferably from 20 to 500g per hectare.
The composition of the present invention may be applied in the form of a formulation on the disease or its growth medium. The compounds of formula I (especially compounds of formula II) are dissolved or dispersed as active ingredients in carriers or formulated so as to be more easily dispersed when used as fungicides. For example: the chemical preparations can be prepared into soluble agents, missible oil, wettable powder, aqueous emulsion, suspending agents, dispersible oil suspending agents, water dispersible granules, seed treatment agents, microcapsule suspending agents, granules, microemulsions, suspension emulsions, suspension-microcapsule suspending agents and the like.
Compared with the prior art, the invention has the following beneficial effects:
compared with the traditional insecticide, the pharmaceutical composition has the following advantages in use:
(1) the composition of the effective component A and the effective component B has a synergistic effect, the usage amount of the composition is greatly reduced compared with that of the composition using a single active component alone, and the prevention and treatment effect is obviously improved; due to the obvious activity of the effective component A to resistant pests, the prevention and control medicine for the important crop diseases and insect pests such as resistant chilo suppressalis, diamond back moth and the like is also solved.
(2) Because of different action mechanisms of the effective component A and the effective component B, the drug resistance of the medicament can be delayed after the composition is compounded, and the composition is an effective resistance risk management tool and prolongs the life cycle of the medicament.
(3) The effective component A and the effective component B are compounded and combined, so that the prevention and control spectrum is expanded, the labor cost of the pesticide is saved, the pesticide composition can be applied to crops such as vegetables, fruit trees, flowers, cereals, oil plants, sugar materials and the like, and various plant diseases and insect pests in gardening, forestry and sanitation, and in addition, the pesticide composition has extremely high activity for emerging Spodoptera frugiperda, can be used for emergency prevention and control, and is favorable for maintaining the ecological safety of the environment and social stability.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Synthetic examples
Synthesis example 1
Preparation of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -benzamido ] -2-fluorobenzamide (compound No. 1):
(1) synthesis of methyl 2-fluoro- [3- (cyclopropylmethyl) amino ] benzoate
Methyl 2-fluoro-3-aminobenzoate (20g, 118.23mmol), bromomethylcyclopropane (20.75g, 153.70mmol), potassium carbonate (21.24g, 153.70mmol) and N, N-dimethylformamide (200mL) were added to the reaction flask in this order, stirred under reflux for 16h, and the heating was turned off to terminate the reaction when TLC monitored that the reaction did not progress. After the reaction solution was cooled to room temperature, water (200mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (100mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: petroleum ether: ethyl acetate: 10: 1) to give 2-fluoro- [3- (cyclopropylmethyl) amino [ methyl benzoate (13g, yield 49.39%) as a pale yellow liquid product.
(2) Synthesis of methyl 2-fluoro-3- [ N- (cyclopropylmethyl) benzamido ] benzoate
Benzoic acid (6.67g, 53.78mmol), toluene (50mL) and thionyl chloride (31.99g, 268.9mmol) were added sequentially to a reaction flask, reacted under reflux for 2h, toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (30mL) until use. Methyl 2-fluoro-3- (N-cyclopropylmethylamino) benzoate (10.00g, 44.82mmol) was dissolved in tetrahydrofuran (100mL), pyridine (4.25g, 53.78mmol) was added thereto, the resulting benzoyl chloride tetrahydrofuran solution was added dropwise, and the mixture was stirred at room temperature for 4 hours. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. The reaction mixture was dissolved in ethyl acetate (50mL), and the organic layer was washed with 2M hydrochloric acid and saturated sodium bicarbonate in this order, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: petroleum ether: ethyl acetate: 8: 1) to give methyl 2-fluoro-3- (N- (cyclopropylmethyl) benzamide) benzoate (13.00g, yield 88.70%) as a colorless liquid.
(3) Synthesis of 2-fluoro-3- [ N- (cyclopropylmethyl) benzamido ] benzoic acid
Methyl 2-fluoro-3- (N- (cyclopropylmethyl) benzamide) benzoate (13.00g, 40.88mmol) was dissolved in methanol (100mL), and 10% aqueous sodium hydroxide (6.54g, 163.52mmol, 65.4mL) was added thereto, and after stirring at room temperature for 2 hours, the reaction was monitored by TLC for completion. After removing methanol by concentration under reduced pressure, the concentrated residue was dissolved in water (100mL), extracted with ethyl acetate (50mL), the organic phase was discarded, the pH of the aqueous phase was adjusted to 7 with 2M aqueous hydrochloric acid solution, extraction was continued with ethyl acetate (100mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a colorless solution product, 2-fluoro-3- [ N- (cyclopropylmethyl) benzamide ] benzoic acid (12.00g, yield 93.82%), which was left overnight to stand as a white solid.
(4) Synthesis of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) benzamido ] -2-fluorobenzamide
2-fluoro-3- (N- (cyclopropylmethyl) benzamido) benzoic acid (0.40g, 1.28mmol), toluene (6mL), thionyl chloride (0.75g, 6.40mmol) were added to a reaction flask in this order, and the reaction was stirred at 140 ℃ for 2 hours, concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (3mL) for further use.
Dissolving 2-bromo-6-trifluoromethyl-4-heptafluoroisopropylaniline (0.52g, 1.28mmol) in tetrahydrofuran (4mL), dropwise adding lithium diisopropylamide (0.77mL, 1.54mmol) at-70 ℃, dropwise adding the tetrahydrofuran solution of the 2-fluoro-3- [ N- (cyclopropylmethyl) benzamido ] benzoyl chloride synthesized in the previous step after 5min, stirring at-70 ℃ for 30min, raising the temperature to room temperature, and continuing to stir for 30 min. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Water (20mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate ═ 3:1) to give N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -benzoylamino ] -2-fluorobenzamide (0.25g, yield 27.84%).
Process for preparation of Compound 11H NMR(400MHz,CDCl3-d),δ[ppm]：8.15(d,J＝2.1Hz,1H),8.03(br s,2H),7.92(d,J＝2.1Hz,1H),7.55(br s,1H),7.35-7.21(m,5H),3.84(d,J＝93.6Hz,2H),1.14(br s,1H),0.59-0.40(m,2H),0.20(d,J＝42.2Hz,2H)。
Synthesis example 2
Synthesis of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6-trifluoromethoxyphenyl ] -3- [ N- (cyclopropylmethyl) benzamido ] -2-fluorobenzamide (Compound No. 3)
2-fluoro-3- (N- (cyclopropylmethyl) benzamide) benzoic acid (0.50g, 1.60mmol), toluene (6mL), and thionyl chloride (1.07g, 9.00mmol) were added to a reaction flask in this order, and the reaction was stirred under reflux for 2 hours, toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (3mL) for further use.
Dissolving 2-bromo-4-heptafluoroisopropyl-6-trifluoromethoxyaniline (0.68g, 1.60mmol) in tetrahydrofuran (4mL), dropwise adding 2M lithium diisopropylamide tetrahydrofuran solution (0.96mL, 1.93mmol) at-70 ℃, dropwise adding the tetrahydrofuran solution for later use after 5min, stirring at-70 ℃ for 30min, heating to room temperature, and continuing stirring for 30 min. The reaction was terminated when the reaction was no longer proceeding as monitored by Thin Layer Chromatography (TLC). Water (20mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (20mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate 5: 1) to obtain the objective product (0.24g, yield 20.50%) as a white solid.
Process for preparation of Compound 31HNMR(400MHz,CDCl3D) data as follows (δ [ ppm ])])：8.01-7.81(m,2H),7.58–7.51(m,3H),7.35-7.21(m,6H),3.85(d,J＝64.0Hz,2H),1.20-1.13(m,1H),0.50(d,J＝7.8Hz,2H),0.20(d,J＝32.0Hz,2H).
Synthesis example 3
Preparation of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -4-cyanobenzamido ] -2-fluorobenzamide (compound No. 4):
(1) synthesis of methyl 2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzamido ] benzoate
4-Cyanobenzoic acid (0.80g, 5.38mmol), toluene (6mL), and thionyl chloride (3.2g, 26.9mmol) were added to a reaction flask in this order, and the mixture was stirred under reflux for 2 hours, toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (3mL) for further use. Methyl 2-fluoro- [3- (cyclopropylmethyl) amino ] benzoate (1.0g, 4.48mmol) was dissolved in tetrahydrofuran (6mL), triethylamine (0.74g, 5.38mmol) was added, a solution of 4-cyanobenzoyl chloride in tetrahydrofuran was added dropwise, and the mixture was stirred at room temperature for 4 hours. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Water (20mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: petroleum ether: ethyl acetate: 3:1) to give methyl 2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzamide ] benzoate (1.40g, yield 88.83%) as a colorless liquid product.
(2) Synthesis of 2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzamido ] benzoic acid
Methyl 2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzamido ] benzoate (1.40g,3.96mmol) was dissolved in methanol (20mL), 10% aqueous sodium hydroxide (0.63g,15.86mmol,6.3mL) was added, the mixture was stirred at room temperature for 2h, and the reaction was monitored by TLC for completion. After removing methanol by concentration under reduced pressure, the concentrated residue was dissolved in water (20mL), extracted with ethyl acetate (10mL), the organic phase was discarded, the pH of the aqueous phase was adjusted to 7 with 2M aqueous hydrochloric acid solution, and further extracted with ethyl acetate (10mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzoylamino ] benzoic acid (1.30g, yield 96.79%) as a white solid.
(3) Synthesis of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -4-cyanobenzamido ] -2-fluorobenzamide:
2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzamide ] benzoic acid (0.75g, 2.22mmol), toluene (6mL) and thionyl chloride (1.31g, 11.10mmol) were added to a reaction flask in this order, the reaction was stirred under reflux for 2h, concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (3mL) for use.
Dissolving 2-bromo-6-trifluoromethyl-4-heptafluoroisopropylaniline (0.90g, 2.22mmol) in tetrahydrofuran (4mL), dropwise adding lithium diisopropylamide (1.30mL, 2.66mmol) at-70 ℃, dropwise adding the 2-fluoro-3- [ N- (cyclopropylmethyl) -4-cyanobenzamide ] benzoyl chloride tetrahydrofuran solution prepared in the previous step after 5min, stirring at-70 ℃ for 30min, heating to room temperature, and continuing to stir for 30 min. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. To the reaction mixture was added a saturated aqueous ammonium chloride solution (20mL), extracted with ethyl acetate (20mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate ═ 3:1) to give N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -4-cyanobenzoylamino ] -2-fluorobenzamide (0.24g, yield 14.91%).
Process for preparation of Compound 41H NMR(400MHz,CDCl3-d),δ[ppm]：8.14(d,J＝2.0Hz,1H),8.12-7.94(m,2H),7.91(t,J＝1.4Hz,1H),7.58-7.39(m,4H),7.32(t,J＝7.9Hz,1H),3.81(dd,J＝76.0,18.8Hz,2H),1.11(br s,1H),0.5(br s,2H),0.20(d,J＝36.7Hz,2H)。
Synthesis example 4
Preparation of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -4- (trifluoromethyl) benzamido ] -2-fluorobenzamide (compound No. 7):
(1) 2-fluoro-3- [ N- (cyclopropylmethyl) -4-trifluoromethylbenzamide ] benzoic acid (0.45g, 1.12mmol), toluene (6mL), and thionyl chloride (0.67g, 5.60mmol) were added to a reaction flask in this order, and the reaction was stirred under reflux for 2 hours, toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (3mL) for further use.
(2) Dissolving 2-bromo-6-trifluoromethyl-4-heptafluoroisopropylaniline (0.46g, 1.12mmol) in tetrahydrofuran (4mL), dropwise adding lithium diisopropylamide (0.70mL, 1.42mmol) at-70 ℃, dropwise adding the tetrahydrofuran solution for later use in the previous step after 5min, stirring at-70 ℃ for 30min, heating to room temperature, and continuing stirring for 30 min. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Water (20mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (20mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate ═ 3:1) to obtain the objective product (0.11g, yield 13.75%).
Process for preparation of Compound 71H NMR(400MHz,CDCl3-d)δ[ppm]：8.21-7.79(m,4H),7.66-7.28(m,5H),3.85(d,J＝104.7Hz,2H),1.12(br s,1H),0.51(br s,2H),0.20(d,J＝42.7Hz,1H)。
Synthesis example 5
Preparation of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -4-fluorobenzamido ] -2-fluorobenzamide (Compound No. 8) as follows:
2-fluoro-3- [ N- (cyclopropylmethyl) -4-fluoro-benzamide ] benzoic acid (2.20g, 6.67mmol), toluene (20mL), thionyl chloride (3.97g, 33.35mmol) were added to the reaction flask in this order, stirred under reflux for 2h and concentrated under reduced pressure to give 2-fluoro-3- [ N- (cyclopropylmethyl) -4-fluorobenzamide ] benzoyl chloride. 2-bromo-6-trifluoromethyl-4-heptafluoroisopropylaniline (3.26g, 7.99mmol), N-diisopropylethylamine (1.72g, 13.30mmol) and 4-N, N-dimethylaminopyridine (0.33g, 2.69mmol) were added to 2-fluoro-3- [ N- (cyclopropylmethyl) -4-fluorobenzamide ] benzoyl chloride, respectively, and the mixture was stirred at 120 ℃ for 2 hours, after which time heating was stopped. Water (20mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (20mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent: PE: EA ═ 3:1) to obtain the objective product (1.80g, yield 37.5%).
Process for preparation of Compound 81H NMR(400MHz,DMSO-d6)δ[ppm]：10.56(s,1H),8.41(s,1H),7.95(s,1H),7.70-7.56(m,2H),7.38-7.32(m,3H),7.09(br s,2H),3.69(br s,2H),1.03-1.01(m,1H),0.41-0.39(m,2H),0.08-0.06(m,2H)。
Synthesis example 6
Preparation of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (cyclopropylmethyl) -4-chlorobenzamido ] -2-fluorobenzamide (Compound No. 10) as follows:
(1) 2-fluoro-3- [ N- (cyclopropylmethyl) -4-chlorobenzamide ] benzoic acid (0.60g, 1.76mmol), toluene (6mL), and thionyl chloride (1.04g, 8.80mmol) were added to a reaction flask in this order, and the reaction was stirred under reflux for 2 hours, toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (3mL) for further use.
(2) Dissolving 2-bromo-6-trifluoromethyl-4-heptafluoroisopropylaniline (0.72g, 1.76mmol) in tetrahydrofuran (4mL), dropwise adding lithium diisopropylamide (1.05mL, 2.11mmol) at-70 ℃, dropwise adding the tetrahydrofuran solution for later use in the previous step after 5min, stirring at-70 ℃ for 30min, heating to room temperature, and continuing stirring for 30 min. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Water (20mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (20mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate ═ 3:1) to obtain the objective product (0.15g, yield 11.63%).
Process for preparation of Compound 101H NMR(400MHz,CDCl3-d)δ[ppm]：8.18-7.84(m,4H),7.53(t,J＝7.7Hz,1H),7.37-7.07(m,4H),3.81(d,J＝85.0Hz,2H),1.11(br s,1H),0.49(br s,2H),0.17(d,J＝32.1Hz,2H)。
Synthesis example 7
Preparation of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (1-cyclopropyl-ethyl) -benzamido ] -2-fluorobenzamide (compound No. 2) by the following method:
(1) synthesis of methyl 3- [ N- (1-cyclopropylethyl) amino ] -2-fluorobenzoate
Methyl 2-fluoro-3-aminobenzoate (2.00g, 11.82mmol) was dissolved in 1, 2-dichloroethane (65mL), and cyclopropylmethyl ketone (2.98g, 35.47mmol), trifluoroacetic acid (8.08g, 70.92mmol) and sodium triacetoxyborohydride (7.51g, 35.47mmol) were added in this order at room temperature, and the reaction was heated to 45 ℃ for 1 h. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Adding saturated NaHCO into the reaction solution3The solution (50mL) was extracted with dichloromethane (80mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate 10: 1) to give the objective product (1.50g, yield 53.5%) as a colorless oil.
(2) Synthesis of methyl 3- [ N- (1-cyclopropyl) ethyl) benzamido ] -2-fluorobenzoate
Benzoic acid (1.54g, 12.64mmol), toluene (15mL) and thionyl chloride (6.27g, 52.68mmol) were added to a reaction flask in this order, the reaction was stirred under reflux for 2h, toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (5mL) for use.
Methyl 3- [ N- (1-cyclopropyl) ethyl) amino ] -2-fluorobenzoate (2.50g, 10.54mmol) was dissolved in tetrahydrofuran (15mL), triethylamine (1.60g, 15.80mmol) and a tetrahydrofuran solution of the acid chloride prepared in the previous step were added in this order, and the reaction was stirred at 80 ℃ for 6 h. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Water (50mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (60mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate 10: 1) to obtain the objective product (1.03g, yield 28.6%) as a yellow solid.
(3)3- [ N- (1-cyclopropyl) ethyl) benzamido ] -2-fluorobenzoic acid
Methyl 3- [ (1-cyclopropyl-ethyl) benzamido ] -2-fluorobenzoate (1.00g, 2.93mmol) was dissolved in methanol (10mL), 10% aqueous sodium hydroxide (0.46g, 11.72mmol, 4.6mL) was added, stirring was carried out at room temperature for 2h, and the reaction was monitored by TLC for completion. After removing methanol by concentration under reduced pressure, the concentrated residue was dissolved in water (20mL), extracted with ethyl acetate (10mL), the organic phase was discarded, the pH of the aqueous phase was adjusted to 3 with 2M aqueous hydrochloric acid solution, extraction was continued with ethyl acetate (10mL), the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the objective product (0.60g, yield 62.6%).
(4) Synthesis of N- [ 2-bromo-4- (1,1,1,2,3,3, 3-heptafluoropropan-2-yl) -6- (trifluoromethyl) phenyl ] -3- [ N- (1-cyclopropyl-ethyl) benzamido ] -2-fluorobenzamide
To a reaction flask were added 3- (N- (1-cyclopropyl) -ethyl) benzamido) -2-fluorobenzoic acid (0.60g, 1.83mmol), toluene (6mL) and thionyl chloride (1.09g, 9.16mmol) in this order, and the reaction was stirred at 140 ℃ for 2h, the toluene was concentrated under reduced pressure, and the concentrated residue was dissolved in tetrahydrofuran (2mL) for further use.
Dissolving 2-bromo-6-trifluoromethyl-4-heptafluoroisopropylaniline (0.75g, 1.83mmol) in tetrahydrofuran (6mL), dropwise adding lithium diisopropylamide (1.10mL, 2.20mmol) at-70 ℃, dropwise adding the tetrahydrofuran solution for later use in the previous step after 5min, stirring at-70 ℃ for 30min, heating to room temperature, and continuing stirring for 30 min. The reaction was terminated by TLC monitoring until the reaction did not proceed any more. Water (20mL) was added to the reaction mixture, and extraction was performed with ethyl acetate (20mL), and the organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was purified by column chromatography (eluent was petroleum ether: ethyl acetate ═ 5: 1) to obtain the objective product (0.23g, yield 17.5%) as a yellow solid.
Process for preparation of Compound 21H NMR(400MHz,CDCl3-d),δ[ppm]：8.19(s,1H),8.05-7.95(m,1H),7.89(s,1H),7.77-7.73(m,1H),7.56-7.52(m,1H),7.28-7.11(m,6H),4.26-4.23(m,1H),1.63(br s,2H),1.51(br s,1H),0.89–0.40(m,5H)。
In addition to the above-described compounds, some of the compounds in Table 1 were prepared by a similar method as in Synthesis examples 1 to 7, and nuclear magnetic data of some of the compounds synthesized by reference to Synthesis examples 1 to 7 are given in Table 4 below.
TABLE 4
Other compounds of formula I of the present invention may be synthesized by reference to the methods described above.
Formulation examples
The following examples are provided to illustrate the composition ratios and preparation of the present invention:
formulation example 1:10% compound 8. hexaflumuron emulsifiable concentrate
The composition of the 10% compound 8. hexaflumuron emulsion is shown in table 5 below:
TABLE 5
Name (R)
Pleated (W/W,%)
Remarks for note
Compound 8
5
Active ingredient A
Hexaflumuron
5
An active ingredient B
Calcium dodecyl benzene sulfonate
8
Emulsifier
Castor oil polyoxyethylene ether
8
Emulsifier
No. 200 solvent oil
Complement 100
Solvent(s)
The preparation method comprises the following steps: calculating the amount of each material according to the formula, adding 200 # solvent oil into a material mixing kettle, adding the compound 8 and hexaflumuron into the kettle for complete dissolution, adding the calcium dodecyl benzene sulfonate and the castor oil polyoxyethylene ether, stirring the mixture for 1.5 hours at the temperature of 40-50 ℃, filtering the mixture, and recording the 10% compound 8-hexaflumuron missible oil.
Formulation example 2:25% compound 4-carbosulfan suspension seed coating agent
The composition of the 25% compound 4 carbosulfan suspension seed coating is shown in table 6 below:
TABLE 6
The preparation method comprises the following steps: adding deionized water, the compound 4, carbosulfan, FS3000, TER4894, kasons, SAG1522 and propylene glycol into a batching kettle according to the material proportion, shearing, sanding, controlling the particle size to be about 905 micrometers, transferring into a blending kettle, adding a 2% xanthan gum solution and a pigment F2R, mixing and stirring for 1 hour to obtain the 25% compound 4. carbosulfan.
Formulation example 3:35% of compound 6 tebufenozide water dispersible granule
The composition of 35% compound 6 tebufenozide water dispersible granules is shown in the following table 7:
TABLE 7
The preparation method comprises the following steps: calculating the amount of each material according to the formula, uniformly mixing the compound 6, the tebufenozide, the sodium dodecyl sulfate, the sodium lignosulfonate, the sodium naphthalene formaldehyde polymer sulfonate, the ammonium sulfate, the corn starch and the kaolin, crushing the mixture to an average particle size of 10-15 microns by using an air flow crusher, adding water accounting for 17% of the powder amount, kneading the mixture, performing rotary extrusion granulation, drying the mixture for 3 hours at 50 ℃, and screening the mixture to obtain the 35% compound 6 tebufenozide water dispersible granule.
Formulation example 4:15% of compound 8-ethofenprox suspending agent
The composition of the 15% compound 8-ethofenprox suspension is shown in table 8 below:
TABLE 8
Name (R)
Pleated (W/W,%)
Remarks for note
Compound 8
10
Active ingredient A
Ether chrysanthester
5
An active ingredient B
Fatty alcohol polyoxyethylene ether
1.5
Wetting agent
Tristyrylphenol polyoxyethylene ether phosphate ester
2
Dispersing agent
Lignosulfonic acid sodium salt
3
Dispersing agent
Propylene glycol
4
Antifreezing agent
1% xanthan gum solution
10
Thickening agent
Kathon
0.1
Preservative
Polydimethylsiloxane
0.2
Organic silicon defoaming agent
Deionized water
Complement 100
Carrier
The preparation method comprises the following steps: calculating the amount of each material according to the formula, uniformly stirring and dissolving deionized water, propylene glycol, tristyrylphenol polyoxyethylene ether phosphate, sodium lignosulphonate, kathon and a defoaming agent, adding ethofenprox and the compound 8, uniformly shearing, grinding by a sand mill until the average particle size is 2 microns, adding 10 parts of 1% xanthan gum solution, and stirring for 30 minutes to obtain the 15% compound 8-ethofenprox suspending agent.
Formulation example 5:5% compound 10-efficient cyhalothrin microcapsule suspending agent
The composition of a 5% compound 10-lambda-cyhalothrin microcapsule suspension is shown in table 9 below:
TABLE 9
The preparation method comprises the following steps: calculating the material amount according to the formula, and uniformly dissolving the compound 10, the efficient cyhalothrin, the polyarylpolymethylene polyisocyanate and the trimethylbenzene at 40-50 ℃ to be used as an A phase; dissolving deionized water, D-800 and propylene glycol uniformly to obtain phase B; slowly adding the phase A into the phase B under high shear, shearing to an average particle size of 2-3 microns, then adding the materials into a three-neck flask, adding hexamethylene diamine, stirring and reacting for 10 hours at 50-60 ℃, adding tristyrylphenol polyoxyethylene ether phosphate, karson, a defoaming agent and 1% xanthan gum solution, and stirring for 1 hour to obtain the 5% compound 10-efficient cyhalothrin microcapsule suspending agent.
Formulation example 6:25% compound 6-pirimicarb wettable powder
The composition of 25% compound 6-pirimicarb wettable powder is shown in table 10 below:
watch 10
Name (R)
Pleated (W/W,%)
Remarks for note
Compound 6
5
Active ingredient A
Pirimicarb
20
An active ingredient B
Sodium dodecyl sulfate
1.5
Wetting agent
Lignosulfonic acid sodium salt
6
Dispersing agent
Kaolin clay
Complement 100
Carrier
The preparation method comprises the following steps: calculating the material amount according to the formula, adding the compound 6, the pirimicarb, the sodium dodecyl sulfate, the sodium lignosulfonate and the kaolin into a material preparation kettle, uniformly mixing, and crushing to obtain 25% compound 6-pirimicarb wettable powder with the average particle size of 10 microns by using a jet mill.
Formulation example 7:50% Compound 7 monosultap dispersible agent
The composition of the 15% compound 7-monosultap dispersible formulation is shown in table 11 below:
TABLE 11
Name (R)
Pleated (W/W,%)
Remarks for note
Compound 5
5
Active ingredient A
Monosultap
10
An active ingredient B
No. 100 solvent oil
15
Solvent(s)
Cyclohexanone
10
Solvent(s)
Castor oil polyoxyethylene ether (EL40)
5
Dispersing agent
Fatty alcohol polyoxyethylene ether
10
Wetting agent
Polydimethylsiloxane emulsion (SAG1522)
0.2
Defoaming agent
Deionized water
Complement 100
Carrier
The preparation method comprises the following steps: adding No. 100 solvent oil and cyclohexanone into a batching kettle according to a process proportion, adding the compound 7 and the fluoro-oxazole amide under stirring, heating to 50 ℃ until the solvent is completely dissolved, adding EL40, fatty alcohol-polyoxyethylene ether and SAG1522, continuing stirring for 10 minutes, cooling, and adding deionized water to obtain the 15% compound 7-monosultap dispersible agent.
Formulation embodiment agent 8: 18% compound 1-chlorpyrifos aqueous emulsion
The composition of the 18% compound 1 chlorpyrifos emulsion in water is shown in table 12 below:
TABLE 12
Name (R)
Pleated (W/W,%)
Remarks for note
Compound 1
8
Active ingredient A
Chlorpyrifos
10
An active ingredient B
No. 150 solvent oil
15
Cosolvent
TERMUL5030
5.0
Emulsifier
Propylene glycol
5.0
Antifreezing agent
SAG1572
0.2
Defoaming agent
Deionized water
Complement 100
Continuous phase
The preparation method comprises the following steps: adding No. 150 solvent oil into a batching kettle, starting stirring, adding the compound 1, stirring for dissolving, adding chlorpyrifos and an emulsifier TERMUL5030 after complete dissolution, continuing stirring for 20 minutes, and uniformly mixing to obtain an oil phase for later use; adding deionized water, a defoaming agent and an antifreezing agent into a shearing kettle, starting a shearing device, slowly adding an oil phase material after 5 minutes, and shearing for 10 minutes after the addition to obtain the 18% compound 1-chlorpyrifos aqueous emulsion.
Bioassay examples
The following examples are intended to illustrate some of the practice of the present invention and the present invention is not limited to the following examples.
Bioassay example 1:the active ingredient A is a compound shown as a formula II, and has remarkable insecticidal activity on various pests
Target: the 3 rd larva of diamondback moth, the 3 rd larva of armyworm and the 3 rd larva of chilo suppressalis are all raised indoors.
The method comprises the following steps: a diamondback moth and leaf soaking feeding method, a armyworm and leaf soaking feeding method, and a chilo suppressalis and rice stem soaking method.
Diamondback moth and leaf soaking feeding method. With reference to NY/1154.14-2008, the main operations are described as follows: soaking clean bracteatum leaf dishes in the liquid medicine for 10s, airing, placing in culture dishes with 4 dishes in each dish, and placing filter paper in the culture dishes for moisture preservation. Each dish was inoculated with 10 plutella xylostella test insects, and the procedure was repeated 3 times. Placing in a light incubator at 25 deg.C under 14hL:10hD for culture. And (5) investigating the number of dead and live plutella xylostella insects 3 days after the application of the composition, and calculating the mortality.
Feeding method with armyworm and soaked leaves. With reference to NY/1154.14-2008, the main operations are described as follows: soaking clean corn leaf segments in the medicinal liquid for 10s, air drying, placing in culture dish with 4 pieces per dish, and placing filter paper in the culture dish for keeping moisture. Each dish was inoculated with 10 test insects of armyworm, and the procedure was repeated 3 times. Placing in a light incubator at 25 deg.C under 14hL:10hD for culture. The number of dead and live armyworms of armyworms is investigated 3 days after the drug administration, and the death rate is calculated.
Chilo suppressalis and rice stem soaking method. Referring to NY/T1154.11-2008, the main operations are as follows: soaking clean rice stem in the medicinal liquid for 10s, taking out, air drying in shade, placing into finger tube, inoculating 10 Chilo suppressalis larva of 3 years old, repeating for 3 times, sealing the tube with cotton black cloth, fastening with rubber band, and culturing in light incubator at 28 deg.C in dark. The number of dead and live chilo suppressalis insects is investigated 3 days after the drug administration, and the mortality rate of each drug treatment is calculated.
The results are shown in Table 13, and it can be seen from the results that the compounds 1-14 have excellent insecticidal activity against diamond back moth, armyworm and chilo suppressalis, and the mortality rate is 100% at dosages of 1mg/L of diamond back moth, 0.4mg/L of armyworm and 10mg/L of chilo suppressalis.
TABLE 13 indoor insecticidal Activity of Compounds 1-14 against Plutella xylostella, armyworm, Chilo suppressalis
Bioassay example 2:the active ingredient A is a compound of a formula II and the active ingredient B is a composition of chlorpyrifos, acephate, phoxim, dichlorvos, fenitrothion, profenofos, triazophos and the like, and the activity test on armyworms is carried out
Target: armyworm, 3 rd instar larva
The method comprises the following steps: and (4) an insect soaking method. The operation is described as follows: with reference to NY/1154.6-2006, the main operations are described as follows: soaking 10 test insects into the liquid medicine for 10s, airing, placing into culture dishes, placing 4 clean corn leaf segments into each dish, and placing filter paper in each culture dish for moisture preservation. 3 replicates. Placing in a light incubator at 25 deg.C under 14hL:10hD for culture. The number of dead and live armyworms of armyworms is investigated 3 days after the drug administration, and the death rate is calculated.
The evaluation methods and criteria were as follows:
the synergistic effect is the percent of actual mortality to the percent of theoretical mortality
Theoretical mortality ═ 1-the mortality of active ingredient a at this dose (1-the mortality of active ingredient B at this dose)
The synergistic effect is more than or equal to 20, and the obvious synergistic effect is shown; the synergistic effect is more than or equal to 10 and less than 20, which represents the synergy; -10. ltoreq. synergistic effects < 10, indicating addition; the synergistic effect is less than-10, which represents antagonism, and the larger the negative value is, the greater the antagonism degree is.
The results are shown in table 14, and it can be seen from the results that the compounds 3, 5, 8 and 10 have excellent activity against armyworm, chlorpyrifos, acephate, phoxim, dichlorvos, fenitrothion, profenofos and triazophos have good activity against armyworm, and the combined action shows synergy or significant synergy after the two are combined.
TABLE 14 indoor pesticidal Activity of test Agents against armyworms
Bioassay example 3:the active ingredient A is a compound shown in the formula II and the active ingredient B is a composition of pesticides such as efficient cyhalothrin, deltamethrin, cypermethrin, bifenthrin, ethofenprox, fenpropathrin and the like, and the composition is used for testing the activity of the alfalfa aphids
Target: and (4) feeding the 3-day-old myzus persicae indoors.
The method comprises the following steps: and (3) an immersion method. The operation is described as follows: culturing the broad bean seedlings indoors for aphids to eat. If aphid preparation: 5 aphids are inoculated to each broad bean leaf, the adult aphids are removed after 24 hours, and if the aphids are larger than 15 leaves before the test, the leaves are selected for the test. The treatment method comprises the following steps: soaking leaf (with Myzus persicae) in the medicinal liquid for 10s, and repeating for 3 times. Culturing and investigating after treatment: placing in a light incubator at 25 deg.C under 14hL:10hD for culture. The number of dead and alive aphids is investigated 3 days after the pesticide is applied, and the death rate is calculated.
Evaluation method in the same manner as in production example 2.
The results are shown in table 15, and it can be seen from the results that compounds 6, 8 and 11 have excellent activity on aphis medicaginis, and cyhalothrin, deltamethrin, cypermethrin, bifenthrin, ethofenprox and fenpropathrin have good activity on aphis medicaginis, and after the two are combined, the combined action shows synergy or significant synergy.
TABLE 15 indoor insecticidal Activity of test Agents against Medicago sativa aphid
Test agent or combination name
Dosage mg/L
3d mortality%
Theoretical mortality%
Synergistic effect
Mode of combined action
Compound 6
10
57.77
/
/
/
Compound 8
10
60.87
/
/
/
Compound 11
10
53.33
/
/
/
Efficient cyhalothrin
0.4
51.11
/
/
/
Deltamethrin
0.1
46.67
/
/
/
Cypermethrin
2.0
55.56
/
/
/
Biphenthrin
2.0
60.00
/
/
/
Fenpropathrin
4.0
57.77
/
/
/
Ether chrysanthester
5.0
62.22
/
/
/
Compound 8+ lambda-cyhalothrin
10+0.4
100
80.87
19.13
Efficiency enhancement
Compound 6+ deltamethrin
10+0.1
100
77.48
22.52
Significant synergy
Compound 6+ cypermethrin
10+2.0
100
81.23
18.77
Efficiency enhancement
Compound 8+ bifenthrin
10+2.0
100
84.35
15.65
Efficiency enhancement
Compound 11+ fenpropathrin
10+4.0
100
80.29
19.71
Efficiency enhancement
Compound 11+ Ethofenprox
10+5.0
100
82.37
17.63
Efficiency enhancement
Bioassay example 4:the active ingredient A is a compound of a formula II and the active ingredient B is a composition of isoprocarb, methomyl, carbosulfan, pirimicarb and the like, and the composition can be used for testing the activity of brown planthopper
Target: brown planthopper, 3-year-old nymph.
The method comprises the following steps: soaking rice seedling. Reference is made to NY/T1154.11-2008.
The method operation is described as follows: preparation of the medicament: according to the proportion and dosage of experimental design, a certain amount of original drug is weighed, dissolved by N, N-Dimethylformamide (DMF), and then 0.05% of Tween 80 water is added to prepare mother liquor with a certain concentration. 5-7 doses are set in each proportion, and the mother liquor is sequentially diluted to the test dose according to the test design. Medicament treatment: soaking rice seedlings in the liquid medicine for 10s, then placing the rice seedlings into disposable cups, inoculating 15 insects to each cup, sealing the cups by using a preservative film, and treating 45 test insects each time. During medicine soaking, the same medicines are sequentially soaked from low concentration to high concentration, and a blank control and a solvent control are arranged. After the treatment, the mixture is placed in an illumination incubator at the temperature of 28 +/-1 ℃ and the light-dark ratio of 15h to 9 h. And (4) investigating a result: the number of dead and live insects was investigated 3d after the administration. And (5) counting the mortality.
Evaluation method example 2 was evaluated in the same manner as the standard.
The results are shown in table 16, and it can be seen from the results that compounds 1,2, 4 and 8 have excellent activity against brown planthopper, isoprocarb, methomyl, carbosulfan and pirimicarb have good activity against brown planthopper, and the combined action of the two shows synergy.
TABLE 16 indoor insecticidal Activity of test Agents against Nilaparvata lugens
Test agent or combination name
Dosage mg/L
3d mortality%
Theoretical mortality%
Synergistic effect
Mode of combined action
Compound 1
10
60.00
/
/
/
Compound 2
10
51.11
/
/
/
Compound 4
6
55.55
/
/
/
Compound 8
10
71.11
/
/
/
Isoprocarb
40
53.33
/
/
/
Pirimicarb
20
73.33
/
/
/
Methomyl
10
57.77
/
/
/
Carbosulfan
5
64.44
/
/
/
Compound 1+ isoprocarb
10+40
100
81.33
18.67
Efficiency enhancement
Compound 2+ pirimicarb
10+20
100
89.96
13.04
Efficiency enhancement
Compound 4+ methomyl
6+10
100
87.80
18.77
Efficiency enhancement
Compound 8+ carbosulfan
10+5
100
89.73
10.27
Efficiency enhancement
Bioassay example 5:the active ingredient A is a compound of a formula II and the active ingredient B is a composition of monosultap, dimehypo, thiocyclam, cartap and the like, and the composition is used for testing the activity of rice stem borer
Target: and (4) feeding chilo suppressalis 3-instar larvae indoors.
The method comprises the following steps: soaking rice stem. The procedure of example 1 was followed, and the evaluation method of example 2 was followed.
The results are shown in table 17, and it can be seen from the results that the compounds 4, 5, 7, 8, 9, 10, 11, 12 and 13 have excellent activity on chilo suppressalis, monosultap, bisultap, thiocyclam and cartap have good activity on chilo suppressalis, and after the two are combined, the combined action shows synergy or significant synergy.
TABLE 17 indoor insecticidal Activity of test Agents against Chilo suppressalis
Bioassay example 6:testing the activity of armyworm when the effective component A is a compound of a formula II and the effective component B is diflubenzuron, hexaflumuron and tebufenozide
Target: armyworm, 3 rd instar larva
The method comprises the following steps: soaking leaves and feeding. The procedure is as described in test example 1. Evaluation method in the same manner as in production example 2.
The results are shown in table 18, and it can be seen from the results that compounds 3 and 5 have excellent activity against armyworm, diflubenzuron, hexaflumuron and tebufenozide have good activity against armyworm, and the combined effect shows synergy or significant synergy after the two are combined.
TABLE 18 indoor insecticidal Activity of test Agents against armyworms
Test agent or combination name
Dosage mg/L
3d mortality%
Theoretical mortality%
Synergistic effect
Mode of combined action
Compound 3
0.04
60.00
/
/
/
Compound 5
0.04
73.33
/
/
/
Diflubenzuron
2.0
46.67
/
/
/
Hexaflumuron
0.8
50.00
/
/
/
Tebufenozide
1.2
60.00
/
/
/
Compound 3+ diflubenzuron
0.04+2.0
100
78.67
21.33
Significant synergy
Compound 3+ hexaflumuron
0.04+0.8
100
80.00
20.00
Significant synergy
Compound 5+ tebufenozide
0.04+1.0
100
89.33
10.67
Efficiency enhancement
Bioassay example 7:activity test of compound 4 and monosultap composition on chilo suppressalis
Insect sources: and (4) feeding chilo suppressalis 3-instar larvae indoors.
The method comprises the following steps: stem dipping method, the operation is as described in growth example 1. The evaluation method refers to NY/T1154.7-2006, and the co-toxicity coefficient is adopted for evaluation.
The co-toxicity coefficient (CTC value) of the mixture is calculated according to the formula (1), the formula (2) and the formula (3):
in the formula: ATI-actual virulence index of the mixture;
S-LC of Standard drug50In milligrams per liter (mg/L);
M-LC of test Agents50In milligrams per liter (mg/L).
TTI＝A×PA+B×PB·········(2)
In the formula: TTI-theoretical virulence index of the mixture;
A-A agent actual virulence index;
PA-the percentage of agent a in the mixture in percent (%);
b-actual virulence index of agent B;
PBthe percentage of the agent B in the mixture is given in percentage (%).
In the formula: CTC-co-toxicity coefficient; ATI-actual virulence index of the mixture; TTI-theoretical virulence index of the mixture.
The co-toxicity coefficient (CTC) is more than or equal to 120 and shows a synergistic effect; CTC is less than or equal to 80 and shows antagonism; 80 < CTC < 120 showed additive effects.
The results are shown in table 19, and it can be seen from the results that both compound 4 and monosultap have excellent activity against chilo suppressalis; the compound 4 and the monosultap are compounded, the co-toxicity coefficient is 94.75-566.62 when the mixture ratio is 200:1-1:200, and the additive or synergistic effect is shown; the co-toxicity coefficients are all larger than 120 when the mixture ratio is 100:1-1:100, and the synergistic effect is shown.
TABLE 19 Co-toxicity coefficient of combination of Compound 4 and monosultap against Chilo suppressalis
Bioassay example 8:activity test of compound 8 and chlorpyrifos composition on chilo suppressalis
Insect sources: and (4) feeding chilo suppressalis 3-instar larvae indoors.
The method comprises the following steps: stem dipping method, description of operation with growth test example 1, evaluation method with growth test example 7.
The results are shown in table 20, and it can be seen from the results that both compound 8 and chlorpyrifos have better activity on chilo suppressalis; the compound 8 and the chlorpyrifos are compounded, and when the mixing ratio is 150: 1-1: 150, the co-toxicity coefficient is 98.44-230.46, and the co-toxicity coefficient are both shown as additive or synergistic effects; when the ratio is 100:1-1:100, the synergistic effect is shown.
TABLE 20 Co-toxicity coefficient of combination of Compound 8 and Chlorpyrifos against Chilo suppressalis
Bioassay example 9:activity test of combination of compound 7 and isoprocarb against Nilaparvata lugens
Target: brown planthopper, 3-year-old nymph.
The method comprises the following steps: soaking rice seedling. Operation descriptions are given in the same test example 4 and evaluation method in the same test example 7.
The results are shown in table 21, from which it can be seen that compound 7 and isoprocarb have better activity against brown planthopper; the compound 7 and isoprocarb are compounded, the cotoxicity coefficient of 160: 1-1: 160 is 103.40-242.04, the additive or synergistic effect is shown, and when the compounding ratio is 80:1-1:80, the cotoxicity coefficient is greater than 120, and the synergistic effect is shown.
TABLE 21 Co-toxicity factor against Nilaparvata lugens for the combination of Compound 7 and isoprocarb
Bioassay example 10:activity test of a combination of Compound 1 and diflubenzuron against Plutella xylostella
Insect sources: and breeding 3-instar larvae of the plutella xylostella indoors.
The method comprises the following steps: soaking leaves and feeding. Description of the operation the in-situ test example 1 and the statistical evaluation in-situ test example 7 were carried out.
The results are shown in Table 22, and it can be seen from the results that
The compound 1 and the diflubenzuron have good activity on diamond back moths; the compound 1 and the diflubenzuron are compounded, the co-toxicity coefficient of the mixture ratio of 160: 1-1: 160 is 102.51-251.14, and the effect is additive or synergistic; when the ratio is 80:1-1:80, the co-toxicity coefficient is more than 120, and the synergistic effect is shown.
TABLE 22 Co-toxicity factor of combinations of Compound 1 and diflubenzuron against Plutella xylostella
Bioassay example 11:activity test of compound 7 and lambda-cyhalothrin composition on aphis medicaginis
Insect sources: and (4) feeding the 3-day-old myzus persicae indoors.
The method comprises the following steps: example 3 was performed in the same manner as in example 7.
The results are shown in table 23, from which it can be seen that both compound 7 and lambda-cyhalothrin have better activity against aphis medicaginis; the compound 7 and the efficient cyhalothrin are compounded, the co-toxicity coefficient of each mixture ratio of 120: 1-1: 120 is 97.30-416.03, and the effect is additive or synergistic; the co-toxicity coefficient is more than 120 when the ratio is 60: 1-1: 60, and the synergistic effect is shown.
TABLE 23 Co-toxicity coefficient of Compound 7 and lambda-cyhalothrin against Adenophora cerifera
Bioassay example 12:activity test of a combination of Compound 6 and cyromazine against Liriomyza sativae
Insect sources: and (5) feeding the liriomyza sativae indoors.
The method comprises the following steps: the blade dip method, referred to in NY/1154.14-2008, is described mainly in the following: soaking clean iris japonica leaves in the medicinal liquid for 10s, air-drying, placing in culture dishes with 1 piece per dish, and placing filter paper in the culture dishes for moisture preservation. Each dish received 10 larvae of liriomyza sativae, 3 replicates. Placing in a light incubator at 25 deg.C under 14hL:10hD for culture. The number of dead and live insects is investigated by microscopic examination 3 days after the drug administration, and the mortality is calculated.
Evaluation method in the same manner as in production example 7.
The results are shown in table 24, from which it can be seen that both compound 6 and cyromazine have better activity against liriomyza sativae; the compound 6 and cyromazine are compounded, the co-toxicity coefficient of each proportion is 100.99-263.29 in the proportion of 160: 1-1: 160, and the effect is additive or synergistic; the co-toxicity coefficient is more than 120 when the ratio is 80:1-1:80, and the synergistic effect is shown.
TABLE 24 Co-toxicity coefficient of combination of Compound 6 and cyromazine against Liriomyza sativae larvae
Bioassay example 13:activity test of a combination of Compound 14 and pyriproxyfen against Bemisia tabaci
Insect sources: bemisia tabaci, greenhouse potted plant breeding, crop: eggplant.
The method comprises the following steps: the vial cartridge membrane method is described as follows by referring to NY/1154.14-2008, and the main operation is as follows: the medicament is matched with a glass tube to prepare a medicament film, each tube is connected with 10 heads of the bemisia tabaci adults, and the steps are repeated for 4 times. Placing in a light incubator at 25 deg.C under 14hL:10hD for culture. The number of dead and live insects is checked 8 hours after the drug is taken, and the mortality is calculated.
Evaluation method in the same manner as in production example 7.
The results are shown in table 25, from which it can be seen that both compound 14 and pyriproxyfen have better activity against bemisia tabaci; the compound 14 and pyriproxyfen are compounded, the co-toxicity coefficient of each proportion is 99.49-229.94 in the proportion of 160: 1-1: 160, and the effect is additive or synergistic; the co-toxicity coefficient is more than 120 when the ratio is 80:1-1:80, and the synergistic effect is shown.
TABLE 25 Co-toxicity factor of combination of Compound 14 and pyriproxyfen against Bemisia tabaci adults
The applicant states that the present invention is illustrated by the above examples to the pharmaceutical composition containing the isophthalamide and the application thereof, but the present invention is not limited by the above examples, i.e. it does not mean that the present invention must be implemented by the above examples. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
- 上一篇：一种医用注射器针头装配设备
- 下一篇：ε-聚赖氨酸的用途